A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.
about
Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trialsInvestigational drugs to treat methicillin-resistant Staphylococcus aureusWill there ever be a universal Staphylococcus aureus vaccine?Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumoniaIdentification of antigenic components of Staphylococcus epidermidis expressed during human infection.Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions.Staphylococcus aureus capsular polysaccharide types 5 and 8 reduce killing by bovine neutrophils in vitroComparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients.Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model.Novel targeted immunotherapy approaches for staphylococcal infection.Capsule expression by bovine isolates of Staphylococcus aureus from Argentina: genetic and epidemiologic analyses.Genetic and serologic evaluation of capsule production by bovine mammary isolates of Staphylococcus aureus and other Staphylococcus spp. from Europe and the United States.Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus.Clonal associations among Staphylococcus aureus isolates from various sites of infectionStaphylococcus aureus AI-2 quorum sensing associates with the KdpDE two-component system to regulate capsular polysaccharide synthesis and virulence.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA.Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide.Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl beta-1,6 glucosamine specific antibody production using biofilm-embedded bacteria.Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis.Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model.Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.Protein A suppresses immune responses during Staphylococcus aureus bloodstream infection in guinea pigs.Evaluation of the protective immunity of a novel subunit fusion vaccine in a murine model of systemic MRSA infection.Heterogeneity of cell-associated CP5 expression on Staphylococcus aureus strains demonstrated by flow cytometry.Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureusStaphylococcus aureus capsular polysaccharides.Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis).Synthesis of Staphylococcus aureus Type 5 trisaccharide repeating unit: solving the problem of lactamization.Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis modelSynthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection.Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremiaAntibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.Exploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesisMsaB activates capsule production at the transcription level in Staphylococcus aureus.Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.EsxA might as a virulence factor induce antibodies in patients with Staphylococcus aureus infection.Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice
P2860
Q21131308-D162F58B-57FB-4F57-B446-7FDF620E807CQ26780246-AC50C80D-AA63-42B2-A9CF-BA84D67E1C45Q26824837-A99F630E-1CF1-4811-B515-911D957E8833Q28728777-A8118024-55A4-4F36-BD03-B8F914DA6B9DQ33251441-F0D47F58-E70F-4063-8DFC-54F6A6A2F5A3Q33605347-E59BE30B-C8B9-4A06-A316-8D0566E737CAQ33716167-0CBF577E-1072-4CD8-BE53-9E85EA7D27C6Q33716613-7D998289-34AC-4C07-BDFB-602EBD3C37D2Q33767412-716763A9-1DBD-459C-850F-EB7BDEE24741Q33910565-4C6897C9-A40A-4D9D-9153-F421D5DCCC56Q33965596-3C7188CB-096C-4528-9231-4A3A9960D14EQ33968870-246E2DD5-D8A8-43AA-B684-5CDA454C4C30Q33991770-FEAEC27F-EC85-4A7B-8E8F-681265E08810Q34005637-534F09DD-27DA-4A28-8D48-C998FAC7719DQ34045106-AADE79B3-6B5D-47F6-93A1-76367B92D931Q34112608-605B15DC-80D3-4A72-8380-4C651F51DA3EQ34113328-2617FABB-E24B-459A-AFE7-C307A4C21ABDQ34116833-EF0045EE-7F25-446E-91D9-77178797472CQ34128193-495CEAF8-3E96-4D95-9C2D-478370B854DAQ34508443-B18B4CAC-D284-44C1-8CD9-909A89B613A2Q34581644-859F634C-DCCC-4BD2-AE9F-6383F403675FQ34769869-653CA043-FADC-4971-9816-6BBF1944F35BQ34944592-2A7B7696-9A12-4DAF-8282-15D40EDD920DQ35038206-1D7A8807-406C-43AB-B399-302D962ECEE6Q35063930-1A70EFA8-E630-4744-B43C-A3554E2AD696Q35229468-82DBFA04-EAB7-4DDE-BD1F-5220CD7B80F3Q35620548-2B7DF9CC-B66A-4EE1-9678-802BCB82B8A7Q35630504-B47798DD-2698-4007-865C-25B03ABE1A25Q35662677-767F1D7C-9DAB-48F6-B818-3164876DA9A3Q35866253-C3CA20AD-1B62-4E0C-BC6F-E0420F3CA19EQ36184397-AAA97A0B-9D31-4F58-90AD-125C11F1550CQ36213353-F75BAA5F-301C-4457-9357-4FBD97238685Q36277405-1E3AB8BE-F51C-45D4-8DFA-6B8C9158657DQ36313264-9AB207B6-4641-4F4C-81C5-8D3DB1F35A44Q36609408-86363311-D733-44F5-8173-E2F5DA4CB7E0Q36636170-287B2F1E-CCC7-4E19-8212-E69D9E42E8AAQ36966028-E7B082BE-9057-4183-A7FC-1841A8348D15Q36974423-0148A2B7-E139-442F-A0AA-7DF6023AC7C5Q37244565-6C45DBD3-FFDF-488E-81A6-75F7A03594EBQ37263376-234CBB0F-05AE-4C86-BC27-07B24AF032EE
P2860
A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.
description
1996 nî lūn-bûn
@nan
1996 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
A Staphylococcus aureus capsul ...... e against bacterial challenge.
@ast
A Staphylococcus aureus capsul ...... e against bacterial challenge.
@en
type
label
A Staphylococcus aureus capsul ...... e against bacterial challenge.
@ast
A Staphylococcus aureus capsul ...... e against bacterial challenge.
@en
prefLabel
A Staphylococcus aureus capsul ...... e against bacterial challenge.
@ast
A Staphylococcus aureus capsul ...... e against bacterial challenge.
@en
P2093
P2860
P1476
A Staphylococcus aureus capsul ...... e against bacterial challenge.
@en
P2093
P2860
P304
P407
P577
1996-05-01T00:00:00Z